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Summary Deletions and apparent transcriptional abnormalities of the FHIT gene at 3p14.2 have recently been reported in a wide variety of
solid tumours. To determine whether lesions of this gene also occur in leukaemia, we have analysed a total of 97 patients (chronic myeloid
leukaemia, CML, in chronic phase or blast crisis, n = 71; de novo acute leukaemia, n = 26) and 16 normal individuals. Intact FHIT transcripts
from all cases were amplified using RT-PCR. Inaddition,smaller size bands that were less intense than the full-length products were
amplified from several samples from patients with leukaemia and also from normal leucocytes. Sequencing of the small products revealed
that they were derived from FHIT transcripts lacking whole exons. Using single-strand conformation polymorphism analysis, no mutations in
the coding sequence were detected in any patient. Furthermore, loss of heterozygosity was not seen in any of 36 informative patients at
D3S1300 or D3S1481, markers located within the FHIT locus. We conclude that the FHIT gene and other uncharacterized tumour-suppressor
genes at 3p14.2 are unlikely to be involved in the pathogenesis of acute leukaemia or progression of CML from chronic phase to blast crisis.
Moreover, low-abundance FHIT transcripts that lack whole exons are not specific to malignant cells and should not be taken as evidence of
an abnormality in the absence of demonstrable genomic DNA lesions.
Keywords: FHIT; FRA3B; loss of heterozygosity; leukaemia; tumour-suppressor gene; 3p14.2
Allelic deletions of at least three discrete regions of the short arm
of chromosome 3 have been found in diverse human cancers and
may indicate the sites of novel tumour-suppressor genes (Brauch
et al. 1987: Naylor et al. 1987: Zbar et al. 1987: Lisitsyn et al.
1994: Zeiger et al. 1994. 1995: Kastury et al. 1996). One such site
is at 3pl4.2. a location that was first highlighted by a reciprocal
chromosomal translocation. t(3:8)(pl4.2:q24). in a family with
hereditary renal cell carcinoma (RCC: Cohen et al. 1979). This site
also coincides with the most common aphidicolin-inducible fragile
site in humans. FRA3B (Paradee et al. 1995). Recently. a novel
gene. FHIT (fragile histidine triad). that maps to chromosome
3pl4.2 has been implicated as the target of these abnormalities
(Ohta et al. 1996). The human MHIT protein has dinucleoside
5'.5"'-PI.P -triphosphate (Ap A) hydrolase activity and belongs to
a family of proteins that are highly conserved in evolution. The
precise cellular function of these proteins is unclear but they may
be involved in the regulation of DNA replication and signalling
stress responses (Bames et al. 1996). The FHIT locus consists of
ten exons distributed over at least 500 kb and is transcribed as a
1.1 kbnmRNA(Figure l:Ohtaetal. 1996).
Absence of FHIT mRNA has been reported in some head and
neck squamous cell carcinoma (HNSCC) and oesophageal cell
lines (Mao et al. 1996: Zou et al. 1997). but bv far the most
commonly reported FHIT abnormalities in primary tumour
samples are the presence ofsmall aberrant transcripts that lack too
or more exons. Such apparent aberrations have been found using
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reverse transcription polymerase chain reaction (RT-PCR) in a
large proportion of cases of oesophageal and Gastrointestinal
tumours (Ohta et al. 1996). small-cell and non-small-cell lung
carcinomas (Sozzi et al. 1996a). HNSCC (Mao et al. 1996: Virgailio
et al. 1996). Merkel cell carcinomas (Sozzi et al. 1996b) and breast
carcinomas (Neggrini et al. 1996. However. no small transcripts
were detected in colorectal tumours (Thiagalingam et al. 1996).
As FHIT is widely expressed. it may also be involved in the
pathogenesis of other malignancies. The aim of this studv was to
determine whether abnormalities of this gene are found in acute
leukaemia. including blast crisis ofchronic mveloid leukaemia.
MATERIALS AND METHODS
Patient and control samples
Expression of the FHIT gene was evaluated in 119 peripheral
blood (PB) or bone marrow (BM) samples obtained from a total of
97 individuals with leukaemia and 16 normal healthy volunteers.
Leukaemia samples were from patients with chronic mveloid
leukaemia in blast crisis (CML-BC. n = 51). acute mveloid
leukaemia (AML. n = 15). acute lymphoblastic leukaemia (ALL.
n = 8). unclassified acute leukaemia (n = 3) and CML in chronic
phase (CML-CP. n = 26). For six individuals with CML. both
chronic phase and blast crisis samples were analysed. All acute
leukaemia and CML-BC samples contained at least 75%7 blast
cells: all CML-CP samples were derived from patients with 100%
Philadelphia chromosome-positive bone marrow metaphases.
For loss of heterozygosity (LOH) analysis. a total of 44 paired
DNA samples from patients with CML were investigated. DNA
from patients in blast crisis was compared with chronic-phase
DNA (n = 28). buccal epithelial cell DNA (n = 12) orboth (n = 4).
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Figure 1 A schematc representabon of te FHIT gene in 3p14.2 showing the position of te internal mcrosatelilte markers (D3S1300 and D3S1481), FRA3B
fragile site. t(3;8) ftanslocation breakpoint associated with RCC, and fe position of FHIT exons. Back and white boxes represent coding and non-coding exons
respectively (E1-E10)
Table 1 Aberrant transcripts in leukaemic and normal haemopoietic cells
Figure 2 Agarose gel showing nested PCR products of FHIT with normal
sized transcripts (N) as well as aberrant transcripts (A) of various sizes.
Lanes 1-8 are from patients with CML in chronic phase or blast crisis; Lanes
9-15 are from normal bone marrow or peripheral blood leucocytes
RT-PCR
Mononuclear cells v ere isolated using density gradient centrifuga-
tion. and total cellular RNA was prepared by lysis in guanidine
thiocyanate and caesium chloride ultracentrifugation as described
(Sambrook et al. 1989). Two to ten micrograms of total RNA
(equivalent to approximately 10- cells) was used for first-strand
cDNA synthesis using random hexamer primers. The integrity of
all cDNAs was verified by single-step amplification ofthe normal
ABL aene as described (Cross et al. 1993). To test for normal and
abnormal MHIT transcripts. a two-step nested PCR was used to
amplify the entire coding region using primers (5U2. 5Ul. 3D2
and 3DI) and conditions essentially identical to those described
previously (Ohta et al. 1996).
Sequencing
FHIT PCR products were gel purified and directly sequenced in
both orientations by thermal cyclingz with fluorescent dye termina-
tors using primers FHIT-F (5'-TACATCCAGACGGTGGA-3')
and FHIT-R (5'-GGTCT1CAAACTGGTTG-3'). which were
internal to the second-step primers SU1 and 3D1. Reactions were
analysed on an automated sequencer (model ABI 373A. Applied
Biosystems. Foster Citv. CA. USA)
LOH analysis
DNA kA-as extracted as previously described (Lench et al. 1988).
PCR amplification was performed for two polymorphic markers.
D3S1300 and D3S1481. which are located within the FIT gene
(Kastury et al. 1996; Fiaure 1). Oligonucleotide sequences were
obtained from the Genome Data Base (Johns Hopkins University.
Baltimore. MD. USA). Fifty nanograms of genomic DNA from
paired samples was amplified for 33 cycles with denaturation at
Sample type Aberrant transcript Exon 10
(ML) 11-bp Delebon
L1, L2, L3 Delebon exons 4-6 +
L4 Deletion exons 4-6
L5 Deletion exons 4-7 +
L6 Deleton exons 4-8 +
L7 Deleton exons 5-7 +
L8 Deleton exons 7a +
N1. N2 Deleton exons 4-6 +
N3. N4, N5 Deleton exons 5-6 +
N6 Deleton exons 5-8 +
aAppentty normal size on agarose gel. L leukaemia: N. normal
haemopoietic samples.
96°C. annealing at 55°C for D3S1300 and 46 C for D3S1481.
followed by extension at 72 C. Products were labelled by reampli-
fication for three cycles with the addition of 2 gCi [a-'P]dCTP
and fractionated on 6% non-denaturing polyacrylamide gels.
SSCP analysis
Detection of point mutations using single-strand conformation
polymorphism analysis (SSCP) was performed as described previ-
ously (Carapeti et al. 1997). Briefly. jl of FHIT PCR products
encompassing the entire coding region was labelled by reamplifi-
cation for three cycles, including 2 gCi [a-'P]dCTP per reaction
and lowering the cold dCTP final concentration to 3 pN¶. Labelled
products were digested with Bsp12861 to yield fragments of
275 bp. 232 bp and 199 bp for intact FHIT transcripts. Digests
were diluted tenfold in 0.1%7 sodium dodecyl sulphate (SDS).
10 nmr EDTA. denatured by boiling for 5 min and electrophoresed
on 6%7 non-denaturing polyacrylamide gels at room temperature
with or without 8% glycerol.
RESULTS
RT-PCR
After single-step PCR. products of the expected size for the intact
FHIT mRNA were amplified from most samples. but the intensity
ofthe bands was weak. No consistent differences in intensity were
apparent between samples from normal individuals and patients
with leukaemia, including those who had >95%7 blast cells. After
nested PCR. intact FHIT transcripts were amplified from all 103
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Figure 3 Sequence chromatograms showing (A) deletion of exons 4-7 in a
patient with leukaemia, (B) deletion of exons 5-8 in a normal individual and
(C) an 11-bp alternative splice in a normal individual
patient samples and the 16 normal individuals. In addition. one or
more smaller size bands that wvere less intense than the full-length
products (Figure 2) were amplified from several samples from
patients with leukaemia [CML-BC. n = 13 (25%7c): CML-CP. n = 16
(62%5): AML. n = 1 (7%e)] and also from normal individuals [n =
13 (76%)]. Southern analysis indicated that the same small FHIT
products detected by nested PCR were also present after single-
step PCR. No difference in the pattern of amplification products
was seen between CML-CP and -BC samples from the same indi-
vidual for the six cases tested (not shown).
Sequence analysis
Most apparently normal-sized PCR transcripts, as well as some
aberrant splice products. had deletions ofthe first 11 bp ofexon 10
(Figure 3). These deletions are downstream ofthe TGA stop codon
and have been reported previously to result from alternative
splicing (Mao et al. 1996: Yanagisawa et al. 1996). Analysis of 14
representative small PCR products derived from both leukaemia
samples and normal individuals re ealed a range of FHJT tran-
scripts that lacked different combinations ofwhole exons (Table 1.
Figure 3). Fusion products were detected with the following exons
spliced together: exons 3-7 (n = 6). exons 3-8 (n = 1). exons 3-9
(n = 1). exons4-8 (n = 1). exons 6-8 (n = 1). exons4-7 (n = 3) and
exons 4-9 (n = 1).
LOH analysis
Expected-size PCR products of 241 bp for D3S1300 and 104 bp
for D3S1481 were amplified in all cases tested. Of the 44 paired
samples amplified for D3S1300. 29 (66%7) were informative. For
D3S1481. 21 (78%) of the 27 cases tested were informative.
Overall. 36 (82%) ofthe 44 paired samples were informative for at
least one of the loci. LOH was not detected in any of the informa-
tive cases at either locus.
SSCP
SSCP analysis was performed for 67 samples (CML-BC. n = 45:
CML-CP. n =3: AML. n = 14: ALL. n =2: AL. n = 3). In addition
to the 1 -bp deletion in the 3' untranslated region (L7UTR) described
above. band shifts for one fragment were noted for four samples
(6%c). Sequence analysis revealed two previously reported silent
polymorphisms: a C to T change at codon 88 (alanine. GCC -
GCT) and a T to C change at codon 98 (histidine. CAT -* CAC)
(Mao et al. 1996: Thiagalingam et al. 1996: Yanagisawa et al.
1996). No other changes were found.
DISCUSSION
CML is a clonal myeloproliferative disorder that usually presents
in chronic phase but eventually progresses to an acute leukaemia
(blast crisis) in almost all patients. Although the BCR-ABL fusion
gene can be detected in 90-95%c ofcases and plays a central role in
the pathogenesis of chronic phase CML (Melo. 1996). little is
known about the molecular events responsible for the transforma-
tion from chronic phase to blast crisis (Sill et al. 1995). Similarly.
a complete description of the molecular pathogenesis of de noVo
acute leukaemia is lacking.
Allelic deletions at 3p14.2 ha e been reported in a wide variety
of solid tumours and also in chronic lymphocytic leukaemia
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(reviewed in Kok et al. 1997: Gartenhaus. 1997). Several lines of
evidence suggest that the recently described FRIT gene may be the
target of these abnormalities: (1) frequent LOH of polymorphic
markers within the FHIT gene (Man et al. 1996: Shridhar et al.
1996: Sozzi et al. 1996a: Fongs et al. 1997: Gemma et al. 1997:
Zou et al. 1997): (2) the findingr of FHIT intragenic deletions.
some ofwhich are homozygous (Kasturv et al. 1996: Vircilio et al.
1996: Yanaaisawa et al. 1996: Druck et al. 1997): (3) absent or
greatly reduced FHIT expression in some malignant cell lines and
primarv tumours (Mao et al. 1996: Panagopoulos et al. 1996:
Yanagisawa et al. 1996: Zou et al. 1997): and (4) the presence of
small FHIT transcripts that lack one or more exons in both cell
lines and primary turnours (Negnrni et al. 1996: Ohta et al. 1996:
Sozzi et al. 1996b: Virgilio et al. 1996: Fong et al. 1997: Hayashi
et al. 1997: Hendricks et al. 1997: Luan et al. 1997). However.
there is no clear correlation between the findingt ofgenomic dele-
tions and the presence or absence of aberrant FHIT transcripts
(Druck et al. 1997) and. furthermore. onlv a very small number of
cases with point mutations in the coding region of the FHIT gene
have been reported.
In our analysis of patients with CML-BC or de novo acute
leukaemia. we did not find anv evidence for LOH within the FHIT
locus, or any point mutations in the coding sequence. No evidence
was found for reduced expression of the FHIT gene in patients
with leukaemia compared with normal individuals, as indicated bv
the finding that there was no consistent difference in the intensitv
of intact FHIT PCR products after single-step amplification. In
common with several other studies. we found that FHIT was only
weakly detectable by RT-PCR and that it was necessary to perform
nested amplification to obtain sufficient products to be clearly
visible on agarose gels.
After nested PCR. we found several leukaemia samples that
expressed small FHIT transcripts lacking several whole exons.
Importantly, however, these apparently aberrant transcripts were
also found in normal lymphocytes. indicating that they are not
specific to malignant cells. Indeed. small products were found in a
greater proportion of normal individuals than in patients with
leukaemia. suggestingy that they may be more common in lympho-
cytes or more mature mveloid cells than in immature blasts. Small
FHIT PCR products were not only seen after nested RT-PCR but
were also detectable by Southern analysis ofsingle-step amplifica-
tion reactions. indicating that they are not simply derived from
very rare transcripts that were selectively amplified by nested
PCR. In all cases. the relative intensity of the small PCR products
was weak compared with that derived from the intact transcript.
but was similar to that seen in many solid tumours (Ohta et al.
1996: Sozzi et al. 1996a and b: Havashi et al. 1997). In these
studies. it was suggested that the weak intensity ofthe small bands
may have arisen because of the presence of an excess of contami-
nating normal cells. Our data. and those ofothers (van den Berg et
al. 1997: Bugert et al. 1997: Panagopoulos et al. 1997). suggest
that small FHIT transcripts probably arise from a low frequency of
altermative splicing in both normal and malignant cells.
Most studies to date have reported the presence of small FHIT
transcripts that lack exon 8. at least in some cases. This exon
encodes the histidine triad. which is essential for the catalytic
activity of the enzyme (Barnes et al. 1996). Many of the products
that we sequenced from both normal individuals and patients with
leukaemia contained exon 8. but most lacked exon 5. This exon
contains the FHIT initiation codon and. as there is no upstream in
frame ATG. mRN'As lacking exon 5 are unlikely to encode a func-
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tional protein. Exons 6 and 8. however. are in frame. and therefore
the single product detected that lacked only exon 7 transcript could
theoretically encode an FMIT protein.
In summary. our data have demonstrated that the FHIT gene and
other uncharacterized tumour-suppressor genes at 3pl4.2 are
unlikely to be involved in the pathogenesis of acute leukaemia or
progression ofCML from chronic phase to blast crisis. In addition.
we have shown that low-abundance FMIT transcripts that lack
whole exons are not specific to maliwnant cells and should not be
taken as evidence of an abnormality in the absence of demon-
strable genomic DNA lesions. It is likely therefore that the true
incidence of FHIT lesions in some solid tumours is less than that
reported in the literature.
ACKNOWLEDGEMENTS
This work was supported by the Leukaemia Research Fund. RCTA
was supported by CNPq (Conseiho Nacional de Desenvolvimento
Cientffico e Tecnol6gico no. 200995/94-4). Brazil.
REFERENCES
Barnes LD. Garrison PN. Siprashvili Z. Guranowski A. Robinson AK. Ingram SW.
Croce CM. Ohta NI and Huebner K 1996 Fhit. a putative tumor suppressor in
humans. is a dinucleoside 5'.5"'-P .P-triphosphate hs drolase. Biochemisrr- 35:
I I 529-11535
van den Berg A. Draaijers TG. Kok K. Timmer T. van der Veen AY. eldhuis PJUE.
de Leij L. Gerhartz CD. Navlor SL. Smith DI and Bu-s, CHCMI 41997 Normal
FHIT transcripts in renal cell cancer- and lung cancer-deneied cell lines.
including a cell line with a homozg Eous deletion in the FRA3B region. Genes
Chrmomosom Cancer 19: 220-227
Brauch H. Johnson B. Hovis J. Yano T. Gazdar A. Pettengill OS. Graziano S.
Sorenson GD. Poiesz BJ. Minna J. Linehan NI and Zbar B 41987 N Molecular
analvsis ofthe short arm ofchromosome 3 in small-cell and non-small-cell
carcinoma ofthe lung. Engl J .Wed317: 1109-1113
Bugert P. Wilhelm MI and Kosacs G 419974 FHIT gene and the FRA3B renion are
not involved in the eenetics of renal cell carcinomas. Genes Chromosom
Cancer 20: 9-15
Carapeti NI. Goldman JI and Cross NCP 419974 Dominant-negatise mutations of
the Wilms' tumour predisposing gene 4WTl are infrequent in CNIL blast crisis
and de noxvo acute leukaemia. Eur J Haematol 58: 346-3.49
Cohen AJ. Li FP. Berg S. Marchetto DJ. Tsai S. Jacobs SC and Brown RS 1979i
Hereditars- renal-cell carcinoma associated with a chromosomal translocation.
N Enel J Med 301: 592-595
Cross NCP. Hughes TP. Lin F. O'Shea P. Bunge\ I. Nlarks DI. Ferrant P. Nlartiat P
and Goldman JM 419934 Nlinimal residual disease after allogeneic bone
marrow transplantation for chronic myeloid leukaemia in first chronic phase:
correlations swith acute araft versus hoyst disease and relapse. Br J Haemarol 84:
67-74
Druck T. Hadaczek P. Fu T-B. Ohta NI. Siprashvili Z. Baffa R. Negrini NI. Kastur\
K. \eronese NIL. Rosen D. Rothstein J. MIcCue P. Cotticelli NIG. Inoue H.
Croce CNI and Huebner K 419974 Structure and expression of the human FHIT
gene in normal and tumor cells. Cancer Res 57: 504-512
Fong KNI. Biesterveld EJ. \-irmani A. A-istuba I. Sekido Y Bader SA. Ahmadian N.
Ong ST. Rassool FV Zimmerman P\. Giaccone G. Gazdar AF and Nlinna JD
419974 FHIT and FRA3B 3pl1 2 allele loss are common in lung cancer and
preneoplastic bronchial lesions and are associated A-ith cancer-related FMIT
cDNA splicing aberrations. CancerRes 57: 2256-2267
Gartenhaus RB 419974 Allelic loss determination in chronic lymphocvtic leukemia
bs immunomagnetic bead sorting and microsatellite marker anal\sis. Oncogene
1: 375-378
Gemma A. Hagi-ara K- Ke Y Burke LMI. Khan NIA. Nagashima MI. Bennett AP
and Harris CC 419974 FHIT mutations in human primarv gastric cancer.
Cancer Res 57: 1435-1437
Ha%ashi S. Tanimoto K. Hajiro-Nakanishi K. Tsuchi\a E. Kurosumi MI. Higashi Y:
Imai K. Suga K and N'aachi K 419974 AbnormalI EHIT tran..cnpt. in human
breast carcinomas: a clinicopathsological and epidemiolonical analxsis of 61
Japanese cases. Cancer Res 57: 1981-1985
lC) Cancer Research Campaign 1998Hendricks DT. Taylor R. Reed M and Birrer MJ (1997) FHIT gene expression in
human ovarian. endonetrial. and cervical cancer cell lines. Cancer Res 57:
2112-2115
Kasury K Baffa R. Druck T. Ohta M. Cotticelli MG. Inoue H. Negrini M. Rugge
M. Huang D. Croce CM. Palazzo J and Huebner K (1996) Potential
gastrointestinal tumorsuppressor locus at the 3pl4-2 FRA3B site identified by
homozygous deletions in tumor cell lines. CancerRes 56: 978-983
Kok K. Naylor SL and Buys CH (1997) Deletions ofthe short arm ofchromosome 3
in solid tumors and the search for suppressor genes. Ads CancerRes 71: 27-92
Lench N. Stanier P and Williamson R (1988) Simple non-invasive method to obtain
DNA for gene analysis. Lancet 1: 1356-1358
Lisitsyn NA. Leach FS. Vogelstein B and Wigler MH (1994) Detection ofgenetic
loss in tumors by representational difference analysis. ColdSpring Harbor
Svwtp QuantBiol59: 585-587
Luan X. Shi G. Zohouri M. Paradee W. Smith DL Decker HJ and Cannizzaro LA
(1997) The FHIT gene is alternatively spliced in normal kidney and renal cell
carcinoma Oncogene 15: 79-86
Man S. Ellis 10. Sibbering M. Blamey RW and Brook ID (1996) High levels of
allele loss at the FIUT and ATM genes in non-comedo ductal carcinoma in situ
and grade I tubular invasive breast cancers. CancerRes 56: 5484-5489
Mao L Fan Y-H. Lotan R and Hong WK (1996) Frequent abnormalities ofFHIT. a
candidate tumor surppessorgene. in head and neck cancer cell lines. Cancer
Res 56: 5128-5131
Melo JV (1996) The diversity ofBCR-ABL fusion proteins and theirrelationship to
leukemia phenotype. Blood 88: 2375-2384
Naylor SL Johnson BE Minna ID and Sakaguchi AY (1987) Loss ofheterozygosity
ofchromosome 3p markers in small-cell hmg cancer. Nature 329- 451-454
Negrini M, Monaco C. Vorechovsky L. Ohta M Dnrck T. Baffa R. Huebner K and
Croce CM (1996) The FHIT gene at 3pl4.2 is abnormal in breast carcinomas.
CancerRes 56: 3173-3179
Ohta M. Inoue FL Cottcelli MG. Kasnuy K Baffa R. Palazzo J. Siprashvili Z. Mori
M. McCue P. Druck T. Croce CM and Huebner K (1996) The FHIT gene.
spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated
t(3:8) breakpoint, is abnormal in digestive tract cancers. Cell84: 587-597
Panagopoulos L Pandis N. Thelin S. Petersson C. Mertens F. Borg A. Kristoffersson
U. Mitelman F and Aman P(199%) T'he FHIT and PTPRG genes are deleted in
benign proliferative breast disease associated with familial breast cancer and
cytogenetic rearrangements ofchromosome band 3p14. Cancer Res 56:
4871-4875
Panagopoulos L. Thelin S. Mertens F. Mitelman F and Aman P (1997) Variable FHIT
transcripts in non-neoplastic tissues. Genes Chromosom Cancer 19: 215-219
0Canc~er Research Camnpaign 1998
FHITin normal and leukaemichaemopoeeccells 605
Paradee W. Mullins C. He Z. Glover T. Wilke C. Opalka B. Schute J and Smith DI
(1995) Precise localization ofaphidicohn-inducedbreakpoints on the short arm
ofhuman chromosome 3. Genomics 27: 358-361
Sambrook J. Fritsch EF and Maniatis T (eds) ( 1989) Molecular Cloning -A
Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring
Harbor. New York
Shridhar R. Shridhar V. Wang X. Paradee W. Dugan M. Sarkar F. Wilke C. Glover
TW. Vaitkevicius VK and Smith DI (1996) Frequent breakpoints in the 3pl4.2
fragile site. FRA3B. in pancreatic tumors. CancerRes 56: 4347-4350
Sill H. Goldman JM and Cross NCP (1995) Homozygous deletions ofthe p16 tumor
suppressor gene are associated with lymphoid transformation ofchronic
myeloid leukemia Blood 85: 2013-2016
Sozzi G. Veronese ML Negrini M. Baffa R. Cotiucelli MG. hnoue K Torielli S.
Pilotti S. De Gregoono L Pastorino U. Pier MA. Ohta M. Hueboer K and
Croce CM (1996a) The FHIT gene at 3pl4.2 is abnormal in lung cancer. Cell
85: 17-26
Sozzi G. Akler H. Tornielli S. Corletto V. Baffa R- Veronese ML Negrini M. Pilotti
S. Pieroti MA. Huebner K and Croce CM (1996b) Aberrant FHIT transcripts
in Merkel cell carcinoma. CancerRes 56: 2472-2474
Thiagalingam S. Lisitsyn NA. Hamaguchi M. Wigler MH. Wtllson JKV. Markowitz
SD. Leach FS. Kinzler KW and Vogelstein B (1996) Evaluation ofthe FHIT
gene in colorectal cancers. CancerRes 56: 2936-2939
Vrgio L Shuster M, Gollin SM. Veronese ML Ohta M. Huebner K and Croce CM
(1996) FHIT gene alterations in head and neck squamous cell carcinomas. Proc
NatlAcad Sci USA 93: 977(-9775
Yanagisawa K Kondo M. Osada H. Uchida K. Takagi K Masuda A. Takahashi T
and Takahashi T (1996) Molecular analysis ofthe FHIT gene at 3pl4.2 in lung
cancercell lines. CancerRes 56: 5579-5582
Zbar B. Brauch H. Talmadge C and Linehan M (1987) Loss ofalleles ofloci on the
short arm ofchromosome 3 in renal cell carcinoma Nature 327: 721-724
Zeiger MA. GnarraJR. Zbar B. Linehan WM and Pass HI (1994) Loss of
heterozygosity on the short arm ofchromosome 3 in mesothelioma cell lines
and solid tumors. Genes Chromosom Cancer 11: 15-20
Zeiger MA. Zbar B. Keiser H. Linehan WM and Gnarra JR (1995) Loss of
heterozygosity on the short arm ofchromosome 3 in sporadic. von
Hippel-indau sease-associated. and familial pheochromocyloma Genes
Chromosom Cancer 13: 151-156
Zou T-T. Lei J. Shi Y-Q. Yin J. Wang S. Souza RF. Kong D. Shimada Y. Smolinski
KN. Greenwald BD. Abraham JM. Harpaz N and Meltzer SJ (1997) FHIT gene
alterations in esophageal cancer and ulcerative colitis WUC). Oncogene 15:
101-105
Britsh Journal ofCanecer (1998) 78(5), 601-605